Cencora, Inc. (NYSE:COR) Shares Sold by Eubel Brady & Suttman Asset Management Inc.

Eubel Brady & Suttman Asset Management Inc. decreased its holdings in shares of Cencora, Inc. (NYSE:COR) by 3.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,262 shares of the company’s stock after selling 2,085 shares during the quarter. Cencora accounts for approximately 1.8% of Eubel Brady & Suttman Asset Management Inc.’s holdings, making the stock its 27th biggest position. Eubel Brady & Suttman Asset Management Inc.’s holdings in Cencora were worth $12,676,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of Cencora during the first quarter valued at $25,000. Legacy Bridge LLC purchased a new position in Cencora in the first quarter valued at about $27,000. New Millennium Group LLC purchased a new position in Cencora in the second quarter valued at about $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the first quarter worth about $29,000. Finally, TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the first quarter worth about $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity

In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the sale, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,450,399 shares of company stock worth $1,070,392,799. Company insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.7 %

Shares of COR opened at $236.53 on Tuesday. Cencora, Inc. has a 12-month low of $172.41 and a 12-month high of $247.66. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $46.61 billion, a price-to-earnings ratio of 25.88, a P/E/G ratio of 1.54 and a beta of 0.44. The stock’s 50-day moving average price is $232.44 and its 200 day moving average price is $233.20.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same period in the previous year, the company posted $2.92 earnings per share. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. As a group, research analysts predict that Cencora, Inc. will post 13.61 earnings per share for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. Cencora’s dividend payout ratio is currently 22.32%.

Analyst Ratings Changes

COR has been the subject of a number of analyst reports. Wells Fargo & Company boosted their price target on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Robert W. Baird cut their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Leerink Partners reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $258.13.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.